AstraZeneca, Daiichi Sankyo and Summit Therapeutics have formed a clinical collaboration to evaluate Datroway with ivonescimab across several tumour types, beginning with a Phase 3 study in first-line triple-negative breast cancer. AstraZeneca or Daiichi Sankyo will sponsor the planned combination studies, while each company supplies its own medicine, shares trial costs and retains development and commercial rights to its respective product. The agreement follows AstraZeneca's $2 billion equity investment in Summit, which is intended to support ivonescimab combinations with antibody-drug conjugates and other AstraZeneca oncology medicines. Ivonescimab is approved in China for certain non-small cell lung cancer patients, while the U.S. Food and Drug Administration reviews its Biologics License Application for EGFR-mutated non-small cell lung cancer.